EDITORS NOTE: I (Will) recently did a video on ARA which discusses a recent study that found ARA had positive effects on strength and muscle mass readers will want to check out. The results of this study will be covered HERE and in a future article by Monica. This excellent article below by Monica discusses the safety of ARA supplements and possible health benefits that set the record straight on this fatty acid…
In part 1 I outlined the background to the “ARA is bad” theory, and presented studies that have refuted this notion. Part 1 also explains the importance of distinguishing the different omega-6 fatty acids, LA and ARA, and describes the bell-shaped relationship between ARA and EPA + DHA in cell membranes.
In this part you will learn about safety aspects and potential health benefits (!) of ARA supplementation…
Safety and Health Effects of ARA supplementation
With the bad reputation that ARA has, let’s start by looking at safety data. On a typical modern diet (that includes meat, eggs and fish) the average intake of ARA is approximately 100–200 mg ARA per day.[1-5] Several studies have investigated safety aspects of ARA supplementation in different populations.
When healthy volunteers were given over 7 times the usual intake of ARA (i.e. 1500 to 1700 g ARA per day, compared to usual intake of 200 mg ARA per day) in a 7 week controlled feeding study, no effects on platelet aggregation, bleeding times, the balance of vasoactive metabolites, serum lipid levels, or immune response were observed.[6-10] Likewise, in a recent study on healthy men aged 26-60 years, supplementation with 840 mg ARA per day for 4 weeks had no effect on any metabolic parameter or platelet function.
A study in healthy Japanese men and women aged 55-70 investigated whether ARA supplementation affects clinical parameters involved in cardiovascular, inflammatory, and allergic diseases. Subjects were supplemented with ARA-enriched oil (240 or 720 mg ARA per day) or placebo for 4 weeks, followed by a 4-week washout period. The fatty acid contents of plasma phospholipids, clinical parameters, and AA metabolites were determined at baseline, 2, 4, and 8 weeks. It was found that ARA content in plasma phospholipids in the ARA supplemented groups increased dose-dependently and was almost the same at 2 weeks and at 4 weeks. The elevated ARA content decreased to nearly baseline during a 4-week washout period. Contrary to expectations, during the supplementation and washout periods, no changes were observed in plasma phospholipid EPA and DHA content. There were no changes in clinical blood parameters related to cardiovascular, inflammatory and allergic diseases.